Search the Newsreel

Smith & Nephew plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:SNN) 2026-08-04

Smith & Nephew H1 Profit Rises

(RTTNews) - Smith & Nephew Plc (SNN, SN.L) reported that its first half profit before tax totaled $380 million compared to $362 million, a year ago. For the half year ended June 27, 2026, attributable profit was $303 million compared to $293 million in …

Smith & Nephew (NYSE: SNN) details 839.9M voting shares and treasury stock

Smith & Nephew plc has updated its voting share capital as of July 31, 2026, comprising 839,857,161 ordinary shares with voting rights. This figure excludes 37,876,589 treasury shares from its total issued share capital of 877,733,750 shares. Shareholders are instructed to use the voting …

Nano Dimension and 4 More Stocks See Action From Activist Investors

Activists also report to the SEC on Smith & Nephew, Navigator Holdings, Global Net Lease, and Radcom. Continue Reading

Smith & Nephew Expands Wound Care Portfolio in $22B Market

Smith & Nephew (SNN) is expanding its wound care portfolio and addressing the chronic wound management market, which is projected to grow to over $30 billion by 2030. The company recently launched two new innovations, ALLEVYN COMPLETE CARE Foam Dressing and RENASYS EDGE Negative …

Smith & Nephew PLC (SNN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Smith & Nephew PLC (SNN), highlighting its current valuation score and P/E ratio. The company's valuation score is 5.83, ranking it 190 out of 199 in the Healthcare Equipment & Supplies industry. While the P/E ratio is …

Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew has received De Novo classification from the FDA for its TESSA Spatial Surgery System, marking a significant advancement in Sports Medicine. The system utilizes AI, augmented reality, and advanced imaging for personalized planning and real-time navigation during arthroscopic procedures, initially focusing on femoral …

Smith+Nephew's AI system overlays a 3D bone model in ACL surgery

Smith+Nephew has received FDA De Novo classification for its TESSA Spatial Surgery System, marking a new category for intra-articular orthopedic stereotaxic navigation instruments. The TESSA system uses AI and cloud-based deep learning algorithms to create patient-specific 3D anatomical models from pre-operative scans, which are …

Smith & Nephew agrees to settle ERISA class action with cash payments to plan participants

Smith & Nephew has agreed to a $350,000 settlement in an ERISA class action lawsuit, addressing allegations of excessive managed account service fees in its U.S. savings plan. Participants and beneficiaries from August 30, 2018, to May 13, 2026, are eligible for pro rata …

Smith & Nephew Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, Smith & Nephew plc has approximately 18,547 employees worldwide, marking a 1.3% decline since 2023 but a recovery from a low in 2025 Q1. The company is actively hiring with 1,218 active job postings in 2026, a 44.1% increase from …

Smith & Nephew PLC (SNN) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 84/100

Smith & Nephew PLC (SNN) saw its stock rise by 4.6% to $32.56, but GuruFocus's GF Value indicates it is 1.4% overvalued compared to its intrinsic value of $32.11. Despite this, SNN holds a strong GF Score of 84/100, driven by high profitability and …

Cevian Capital Lifts Smith & Nephew Stake Above 14% in Late-July Disclosure

Smith & Nephew SNATS (SNN) to Announce Quarterly Earnings on Tuesday

Form 13D/A Smith & Nephew plc For: 27 July By Investing.com

This article announces the filing of Form 13D/A for Smith & Nephew plc on July 27th. Form 13D/A is an amendment to a Schedule 13D, which is filed with the SEC when a beneficial owner acquires more than 5% of a company's stock, indicating …

Cevian Capital reports 14.18% Smith & Nephew stake (NYSE: SNN)

Cevian Capital II GP Limited has reported a beneficial ownership of 119,179,419 ordinary shares in Smith & Nephew plc, representing 14.18% of the company's outstanding shares. The investment, totaling approximately $1.67 billion, was funded from Cevian Funds' general working capital, with sole voting and …

Smith & Nephew (NYSE: SNN) shows Cevian at 14.010786% voting stake

Smith & Nephew (NYSE: SNN) reported a significant change in major shareholding, with Cevian Capital II G.P. Limited now holding 14.010786% of voting rights, up from 13.206621%. This holding, totaling 117,912,733 voting rights, is primarily through Cevian Capital II Master Fund L.P. and Cevian …

Smith & Nephew stock holds steady on 2025 revenue and margin gains

Smith & Nephew's stock is supported by strong 2025 financial results, with revenue reaching $5.81 billion and an adjusted operating profit margin of 17.3%. The company demonstrated robust underlying revenue growth and significant margin improvement, indicating its ability to absorb pricing pressures and product-mix …

Smith & Nephew plc Revenue Breakdown – LSE:SN.

Smith & Nephew plc (SNN) latest stock news and headlines

This article provides a compilation of recent news and headlines regarding Smith & Nephew plc (SNN), a medical technology company. It highlights product launches, strategic expansions, expert consensus, and analyst and activist investor opinions affecting the stock's performance. The company's stock performance relative to …

Smith+Nephew Expands ASC Platform to Support Value-Based Care

Smith+Nephew SNN recently unveiled an expanded ASC Solutions strategy aimed at helping ambulatory surgery centers ("ASCs") improve operational efficiency, accelerate growth and deliver better patient outcomes. The enhanced enterprise approach combines the company's procedural technologies, data-driven insights and strategic partner network to support ASC …

Smith & Nephew Advances $250 Million Share Buyback, Repurchasing Over 1 Million Shares in Latest Week

Smith & Nephew has announced the repurchase of 1,069,609 ordinary shares between July 17 and 23, 2026, as part of its $250 million share buyback program. The shares were acquired at an average price of 1,127.68 pence per share. Since the program began on …

Smith & Nephew stock trades steady as surgical portfolio supports earnings

Smith & Nephew's stock remains stable due to strong performance in its orthopedics and sports medicine franchises. The company reported increased revenue of $5.5 billion in fiscal 2024, up from $5.2 billion in 2023, and maintained a mid-teens trading margin despite investments in innovation …

Smith+Nephew (NYSE: SNN) schedules Q2 and H1 2026 results call

Smith+Nephew (NYSE: SNN) has announced it will release its second quarter trading and first half 2026 results on August 4, 2026, at 7:00 AM BST / 2:00 AM EDT. A conference call for financial analysts will follow at 11:30 AM BST / 6:30 AM …

Smith & Nephew stock trades steady as orthopedics margins recover

Smith & Nephew's stock is reflecting improved profitability, driven by margin gains in its orthopedics and sports medicine segments in 2023. The company saw a 6% revenue growth to $5.5 billion in 2023 and increased adjusted trading profit, indicating effective cost control and a …

Bank of America reports 3.172736% voting stake in Smith & Nephew (NYSE: SNN)

Bank of America Corporation has reported a 3.172736% voting stake in Smith & Nephew (NYSE: SNN) through a TR-1 notification. This holding comprises 2.402237% from shares and 0.770499% from financial instruments, including a Right to Recall and various cash-settled swaps. The total voting rights …

Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care

Smith+Nephew has launched an expanded enterprise ASC Solutions Strategy focused on helping ambulatory surgery centers (ASCs) optimize costs, improve quality, and enhance performance. This strategy includes the ASC ONE delivery model, which simplifies ASC development and operations by providing a single point of coordination …

Smith & Nephew stock rises on earnings context and investor focus

Smith & Nephew's stock is gaining attention due to its strong 2025 financial performance, including $5.83 billion in revenue and a 17.9% trading profit margin. The company's underlying revenue growth of 7.6% and efficient conversion of growth into operating leverage are key factors. Investors …

Smith & Nephew (NYSE: SNN) leaders buy ADS through employee stock plan

Three senior leaders at Smith & Nephew plc (NYSE: SNN), including the CEO, President of Global Operations, and President of Sports Medicine, purchased American Depositary Shares (ADS) through the company's Employee Stock Purchase Plan. The transactions, which occurred on July 10, 2026, involved purchases …

Smith+Nephew's ASC ONE provides one coordination point for surgery centers

Smith+Nephew (NYSE: SNN) has launched ASC Solutions, an expanded enterprise strategy for ambulatory surgery centers (ASCs) aimed at optimizing costs, enhancing quality, and improving outcome performance. This strategy includes expanding its ASC ONE delivery model into an integrated platform that coordinates various aspects of …

Smith & Nephew stock trades steady as surgical device margins support guidance

Smith & Nephew stock shows stable performance, with orthopedic and wound-care margins supporting current guidance. The company relies on its diversified portfolio in orthopedics, sports medicine, and advanced wound management, maintaining focus on organic revenue growth and improving trading profit margins. Investors are watching …

Smith & Nephew stock advances on earnings and margin focus

Smith & Nephew's stock movement is being evaluated based on its latest earnings, margin, and cash flow performance. The company, a global medical technology group, focuses on orthopedics, sports medicine, and wound care. Investors are primarily looking at sales growth, margin development, and free …

Smith & Nephew stock holds steady as 2025 revenue and margin guide frame the next update

Smith & Nephew's stock performance is currently framed by its 2025 financial guidance, which includes an expected underlying revenue growth of 4.0% to 5.0%, a trading profit margin of around 19.5%, and cash conversion of approximately 90%. These figures serve as key benchmarks for …

Smith & Nephew stock holds steady as Q1 2026 growth and margin improvement underpin outlook

Smith & Nephew's stock is supported by robust Q1 2026 revenue growth and improving trading profit margins, driven by stronger Orthopaedics demand and disciplined cost control. The company reported increased revenue from $5.5 billion in fiscal 2023 to over $5.8 billion in 2025, with …

Smith & Nephew (SNN) Slips 2.6% as Market Digests Headwinds - Pre-Earnings Momentum

Smith & Nephew stock trades steadily as recent earnings highlight margin focus

Smith & Nephew's recent financial results indicate steady revenue growth but also highlight ongoing margin pressures, driven by cost inflation and R&D investments. The company, which specializes in orthopedics, sports medicine, and advanced wound care, reported approximately $5.5 billion in annual revenue with incremental …

Former Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner

Craig Gaffin, former president of Smith+Nephew's global orthopaedics business, has joined MedEdge Holdings as a partner. MedEdge, founded in 2025, focuses on acquiring, building, and commercializing innovative surgical technology companies and expanding a nationwide commercial infrastructure. Gaffin's extensive commercial leadership experience aims to help …